Deutsch
Español
India
Italiano
Français
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
Deutsch
Español
India
Italiano
Français
Sign in
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Dyne Therapeutics
(NASDAQ:DYN)
Intraday
$24.73
1.035
[4.37%]
After-Hours
$24.73
0
[0.00%]
Get Report
Watch
Perks
Buy
Compare Brokers
$24.73
1.035
[4.37%]
At close: Apr 26
$24.73
0
[0.00%]
After Hours: 4:20PM EDT
Get Report
Watch
Overview
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest News for Dyne Therapeutics Stock (NASDAQ:DYN)
Dyne Therapeutics Stock (NASDAQ: DYN)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Tuesday, March 26, 2024
Oppenheimer Reiterates Outperform on Dyne Therapeutics, Maintains $47 Price Target
Benzinga Newsdesk
-
Mar 26, 2024, 10:07AM
Monday, March 25, 2024
Why Landos Biopharma Shares Are Trading Higher By Over 170%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Avi Kapoor
-
Mar 25, 2024, 2:44PM
Aehr Test Systems Reports Preliminary Results, Joins Dyne Therapeutics, United Airlines And Other Big Stocks Moving Lower On Monday
Avi Kapoor
-
Mar 25, 2024, 10:32AM
Dyne Therapeutics shares are trading lower after the company announced a CEO transition.
Benzinga Newsdesk
-
Mar 25, 2024, 8:35AM
Dyne Therapeutics Has Appointed John Cox As President, Chief Executive Officer And A Member Of The Board Of Directors, Effective Immediately. He Succeeds Joshua Brumm, Who Has Chosen To Step Down
Benzinga Newsdesk
-
Mar 25, 2024, 7:34AM
Thursday, March 14, 2024
Neuromuscular Focused-Avidity Biosciences Has 'Complete Package' - Analyst Predicts Stellar 142% Stock Surge
Vandana Singh
-
Mar 14, 2024, 3:29PM
Friday, March 08, 2024
Chardan Capital Maintains Buy Rating for Dyne Therapeutics: Here's What You Need To Know
Benzinga Insights
-
Mar 8, 2024, 12:00PM
Chardan Capital Maintains Buy on Dyne Therapeutics, Raises Price Target to $31
Benzinga Newsdesk
-
Mar 8, 2024, 3:58AM
Thursday, March 07, 2024
Guggenheim Maintains Buy on Dyne Therapeutics, Raises Price Target to $37
Benzinga Newsdesk
-
Mar 7, 2024, 11:19AM
Wednesday, March 06, 2024
HC Wainwright & Co. Reiterates Buy on Dyne Therapeutics, Maintains $36 Price Target
Benzinga Newsdesk
-
Mar 6, 2024, 12:59PM
Piper Sandler Maintains Overweight Rating for Dyne Therapeutics: Here's What You Need To Know
Benzinga Insights
-
Mar 6, 2024, 12:00PM
Stifel Maintains Buy on Dyne Therapeutics, Raises Price Target to $41
Benzinga Newsdesk
-
Mar 6, 2024, 10:24AM
Piper Sandler Maintains Overweight on Dyne Therapeutics, Raises Price Target to $29
Benzinga Newsdesk
-
Mar 6, 2024, 9:27AM
Tuesday, March 05, 2024
Oppenheimer Reiterates Outperform on Dyne Therapeutics, Raises Price Target to $47
Benzinga Newsdesk
-
Mar 5, 2024, 7:52AM
Recap: Dyne Therapeutics Q4 Earnings
Benzinga Insights
-
Mar 5, 2024, 7:40AM
Dyne Therapeutics Q4 EPS $(1.09) Misses $(0.92) Estimate, Cash Balance of $123.1M
Benzinga Newsdesk
-
Mar 5, 2024, 7:36AM
Friday, March 01, 2024
Cooper Companies Reports Upbeat Results, Joins Dell, NetApp, Tidewater And Other Big Stocks Moving Higher On Friday
Avi Kapoor
-
Mar 1, 2024, 11:18AM
Tuesday, February 20, 2024
HC Wainwright & Co. Initiates Coverage On Dyne Therapeutics with Buy Rating, Announces Price Target of $36
Benzinga Newsdesk
-
Feb 20, 2024, 8:03AM
Thursday, February 15, 2024
Top 4 Health Care Stocks You May Want To Dump In February
Avi Kapoor
-
Feb 15, 2024, 8:15AM
Wednesday, February 14, 2024
Dyne Therapeutics Announces Upcoming Presentations On Initial Clinical Data From Its ACHIEVE Trial In DM1 Patients And DELIVER Trial In DMD Patients At The 2024 Muscular Dystrophy Association Clinical & Scientific Conference
Benzinga Newsdesk
-
Feb 14, 2024, 5:09PM
Friday, January 26, 2024
'Drug Developer Dyne Therapeutics Weigh Options After Takeover Interest' -Bloomberg
Benzinga Newsdesk
-
Jan 26, 2024, 2:50PM
Hearing Dyne Therapeutics Said To Weigh Options Amid Takeover Interest; Shares Halted On Circuit Breaker
Benzinga Newsdesk
-
Jan 26, 2024, 2:31PM
Monday, January 15, 2024
10 Health Care Stocks With Whale Alerts In Today's Session
Benzinga Insights
-
Jan 15, 2024, 12:35PM
Friday, January 12, 2024
$30M Bet On This Healthcare Stock? Check Out These 3 Stocks Insiders Are Buying
Avi Kapoor
-
Jan 12, 2024, 6:38AM
Friday, January 05, 2024
Why Applied Therapeutics Shares Are Trading Lower By Over 35%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Avi Kapoor
-
Jan 5, 2024, 1:13PM
Franklin Covey Shares Fall After Q1 Results, Joins Theravance Biopharma, Voyager Therapeutics And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Avi Kapoor
-
Jan 5, 2024, 6:19AM
Dyne Therapeutics Prices $300M Public Offering Of 17.15M Common Stock At $17.50/Share
Benzinga Newsdesk
-
Jan 5, 2024, 1:31AM
Thursday, January 04, 2024
Dyne Therapeutics shares are trading higher after Raymond James maintained a Strong Buy on the stock and raised its price target from $27 to $56.
Benzinga Newsdesk
-
Jan 4, 2024, 3:39PM
Crude Oil Moves Lower; Walgreens Posts Upbeat Earnings
Avi Kapoor
-
Jan 4, 2024, 2:15PM
Why Mobileye Global Shares Are Trading Lower By Over 23%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Avi Kapoor
-
Jan 4, 2024, 1:37PM
12 Health Care Stocks Moving In Thursday's Intraday Session
Benzinga Insights
-
Jan 4, 2024, 12:31PM
Dow Surges 200 Points; US Services PMI Edges Higher In December
Avi Kapoor
-
Jan 4, 2024, 12:00PM
Lamb Weston Posts Upbeat Results, Joins Omega Therapeutics, Allstate And Other Big Stocks Moving Higher On Thursday
Avi Kapoor
-
Jan 4, 2024, 10:12AM
Cal-Maine Posts Downbeat Q2 Results, Joins Dyne Therapeutics, OPKO Health And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Avi Kapoor
-
Jan 4, 2024, 5:46AM
Raymond James Maintains Strong Buy on Dyne Therapeutics, Raises Price Target to $56
Benzinga Newsdesk
-
Jan 4, 2024, 4:30AM
Wednesday, January 03, 2024
Dyne Therapeutics Announces Underwritten Public Offering Of $175M Of Common Stock
Benzinga Newsdesk
-
Jan 3, 2024, 4:26PM
Dyne Therapeutics shares are trading higher after the company announced initial clinical data from its ACHIEVE trial of DYNE-101 in patients with DM1 and its DELIVER trial of DYNE-251 in patients with DMD.
Benzinga Newsdesk
-
Jan 3, 2024, 1:12PM
Why SoFi Technologies Shares Are Trading Lower By Around 13%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Avi Kapoor
-
Jan 3, 2024, 12:58PM
12 Health Care Stocks Moving In Wednesday's Intraday Session
Benzinga Insights
-
Jan 3, 2024, 12:31PM
TDCX Receives Preliminary Non-binding Proposal Letter, Joins Pure Storage, Dyne Therapeutics And Other Big Stocks Moving Higher On Wednesday
Avi Kapoor
-
Jan 3, 2024, 10:24AM
Why Is Rare Muscle Disease-Focused Dyne Therapeutics Stock Soaring Today?
Vandana Singh
-
Jan 3, 2024, 8:07AM
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga Insights
-
Jan 3, 2024, 8:05AM
Dyne Therapeutics Announces Initial Clinical Data From Its ACHIEVE Trial Of DYNE-101 In Patients With Myotonic Dystrophy Type 1 And DELIVER Trial Of DYNE-251 In Patients With Duchenne Muscular Dystrophy Who Are Amenable To Exon 51
Benzinga Newsdesk
-
Jan 3, 2024, 6:33AM
Friday, November 03, 2023
Dyne Therapeutics Chief Operating Officer Trades $73K In Company Stock
Benzinga Insights
-
Nov 3, 2023, 11:02AM
Monday, October 30, 2023
Dyne Therapeutics shares are trading higher after the company reported Q3 financial results.
Benzinga Newsdesk
-
Oct 30, 2023, 1:36PM
Dyne Therapeutics' Cash, Cash Equivalents And Marketable Securities Of $157.8M, Expected To Provide Cash Runway Through 2024
Benzinga Newsdesk
-
Oct 30, 2023, 7:32AM
Dyne Therapeutics Q3 EPS $(0.99) Misses $(0.83) Estimate
Benzinga Newsdesk
-
Oct 30, 2023, 7:30AM
Tuesday, October 03, 2023
Stocks That Hit 52-Week Lows On Tuesday
Benzinga Insights
-
Oct 3, 2023, 2:37PM
Wednesday, September 20, 2023
Dyne Therapeutics Receives FDA Orphan Drug Designation For DYNE-101 For The Treatment Of Myotonic Dystrophy Type 1
Benzinga Newsdesk
-
Sep 20, 2023, 4:05PM
Wednesday, August 09, 2023
JP Morgan Maintains Overweight on Dyne Therapeutics, Raises Price Target to $22
Benzinga Newsdesk
-
Aug 9, 2023, 12:28PM
Show more
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch